GLP-1-based therapies and the exocrine pancreas: More light, or just more heat?

Diabetes

Volumn 61, Issue 5, 2012, Pages 986-988

  Gale, Edwin A M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; LIRAGLUTIDE; ROSIGLITAZONE; SITAGLIPTIN; TROGLITAZONE;

ACUTE PANCREATITIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PANCREAS CANCER; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; PRIORITY JOURNAL;

ANIMALS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PANCREAS; PANCREATIC DUCTS; PANCREATITIS; PEPTIDES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTORS, GLUCAGON; VENOMS;

EID: 84860544874     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1838     Document Type: Note

References (16)

1. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-990
2. Gale EAM. Collateral damage: the conundrum of drug safety. Diabetologia 2009;52:1975-1982
3. Gier B, Butler PC, Lai CK, et al. Glucagon-like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 2012;97: 121-131
4. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies - review of the scientific evidence. J Clin Endocrinol Metab 2011;96:2027-2031
5. Parnaud G, Bosco D, Berney T, et al. Proliferation of sorted human and rat beta cells. Diabetologia 2008;51:91-100 (Pubitemid 50002201)
6. Rankin MM, Kushner JA. Adaptive beta-cell proliferation is severely restricted with advanced age. Diabetes 2009;58:1365-1372
7. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care 2010;33:453-455
8. Ottenhof NA, Milne AN, Morsink FH, et al. Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: of mice and men. Arch Pathol Lab Med 2009;133:375-381
9. G12D mouse model. Diabetes 2012;61:1250-1262
10. Strobel O, Rosow DE, Rakhlin EY, et al. Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology 2010;138:1166-1177
11. Reichert M, Rustgi AK. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 2011;121:4572-4578
12. Nyborg NC, Mølck A-M, Madsen LW, Bjerre Knudsen L. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-1249
13. Gale EAM. The second time as farce: rosiglitazone and the regulators. Nat Rev Endocrinol 2011;7:5-6
14. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-156
15. Spranger J, Gundert-Remy U, Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology 2011;141:20-23
16. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-2354